Timber Pharmaceuticals, Inc. – AMEX:TMBR
Timber Pharmaceuticals stock price today
Timber Pharmaceuticals stock price monthly change
Timber Pharmaceuticals stock price quarterly change
Timber Pharmaceuticals stock price yearly change
Timber Pharmaceuticals key metrics
Market Cap | 1.17M |
Enterprise value | N/A |
P/E | -0.18 |
EV/Sales | -67.42 |
EV/EBITDA | 0.18 |
Price/Sales | 37.76 |
Price/Book | 0.60 |
PEG ratio | N/A |
EPS | -5.92 |
Revenue | N/A |
EBITDA | -14.17M |
Income | -15.04M |
Revenue Q/Q | N/A |
Revenue Y/Y | -86.85% |
Profit margin | -38410.67% |
Oper. margin | -38204.57% |
Gross margin | 0% |
EBIT margin | -38204.57% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTimber Pharmaceuticals stock price history
Timber Pharmaceuticals stock forecast
Timber Pharmaceuticals financial statements
| Sep 2022 | 0 | -3.17M | |
|---|---|---|---|
| Dec 2022 | 83.17K | -3.62M | -4355.51% |
| Mar 2023 | 0 | -4.18M | |
| Jun 2023 | 0 | -4.06M |
| Sep 2022 | 12790208 | 5.15M | 40.32% |
|---|---|---|---|
| Dec 2022 | 10275968 | 5.04M | 49.06% |
| Mar 2023 | 6276710 | 4.96M | 79.12% |
| Jun 2023 | 3326213 | 5.94M | 178.8% |
| Sep 2022 | -4.13M | 0 | 7.08M |
|---|---|---|---|
| Dec 2022 | -3.19M | -1.13K | 1.05M |
| Mar 2023 | -3.90M | -1.96K | 0 |
| Jun 2023 | -2.65M | 1 | 0 |
Timber Pharmaceuticals alternative data
| Aug 2023 | 9 |
|---|---|
| Sep 2023 | 9 |
| Oct 2023 | 9 |
| Nov 2023 | 9 |
| Dec 2023 | 9 |
| Jan 2024 | 9 |
| Feb 2024 | 9 |
| Mar 2024 | 9 |
| Apr 2024 | 9 |
| May 2024 | 9 |
| Jun 2024 | 9 |
| Jul 2024 | 9 |
Timber Pharmaceuticals other data
| Period | Buy | Sel |
|---|---|---|
| Mar 2021 | 1988 | 0 |
| May 2021 | 0 | 47736 |
| Jun 2021 | 0 | 780714 |
| Aug 2021 | 0 | 725000 |
| Sep 2021 | 0 | 375500 |
| Nov 2021 | 25000 | 0 |
| Dec 2021 | 20000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | ROME ZACHARY director | Value Appreciation Rights | 79,326 | $0.01 | $793 | ||
Option | ROME ZACHARY director | Common Stock, par value $0.001 per share | 79,326 | $0.01 | $793 | ||
Purchase | KOCONIS JOHN director, officer: CEO & Presid.. | Common Stock, par value $0.001 per share | 20,000 | $0.38 | $7,680 | ||
Purchase | MENDELSOHN ALAN officer: Chief Medical Officer | Common Stock, par value $0.001 per share | 10,000 | $0.47 | $4,700 | ||
Purchase | SITAR EDWARD J director | Common Stock, par value $0.001 per share | 15,000 | $0.46 | $6,900 | ||
Sale | TARDIMED SCIENCES LLC 10 percent owner | Common Stock, par value $0.001 per share | 225,000 | $0.94 | $211,050 | ||
Sale | TARDIMED SCIENCES LLC 10 percent owner | Common Stock, par value $0.001 per share | 150,500 | $0.92 | $138,912 | ||
Sale | TARDIMED SCIENCES LLC 10 percent owner | Common Stock, par value $0.001 per share | 150,000 | $0.91 | $136,800 | ||
Sale | TARDIMED SCIENCES LLC 10 percent owner | Common Stock, par value $0.001 per share | 100,000 | $0.93 | $92,700 | ||
Sale | TARDIMED SCIENCES LLC 10 percent owner | Common Stock, par value $0.001 per share | 100,000 | $0.92 | $91,800 |
| Patent |
|---|
Application Filling date: 4 Mar 2019 Issue date: 11 Feb 2021 |
Application Filling date: 4 Mar 2019 Issue date: 11 Feb 2021 |
| Insider | Compensation |
|---|---|
Mr. John Koconis M.B.A. (1970) Chairman, Chief Executive Officer & Pres | $507,260 |
| Mr. Joseph Lucchese (1968) Executive Vice President & Chief Financial Officer | $360,200 |
| Mr. Zachary Rome (1984) Chief Operating Officer, Executive Vice President, Sec. & Director | $300,670 |
-
What's the price of Timber Pharmaceuticals stock today?
One share of Timber Pharmaceuticals stock can currently be purchased for approximately $0.35.
-
When is Timber Pharmaceuticals's next earnings date?
Unfortunately, Timber Pharmaceuticals's (TMBR) next earnings date is currently unknown.
-
Does Timber Pharmaceuticals pay dividends?
No, Timber Pharmaceuticals does not pay dividends.
-
How much money does Timber Pharmaceuticals make?
Timber Pharmaceuticals has a market capitalization of 1.17M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 71.87% to 83.18K US dollars.
-
What is Timber Pharmaceuticals's stock symbol?
Timber Pharmaceuticals, Inc. is traded on the AMEX under the ticker symbol "TMBR".
-
What is Timber Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Timber Pharmaceuticals?
Shares of Timber Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Timber Pharmaceuticals's key executives?
Timber Pharmaceuticals's management team includes the following people:
- Mr. John Koconis M.B.A. Chairman, Chief Executive Officer & Pres(age: 55, pay: $507,260)
- Mr. Joseph Lucchese Executive Vice President & Chief Financial Officer(age: 57, pay: $360,200)
- Mr. Zachary Rome Chief Operating Officer, Executive Vice President, Sec. & Director(age: 41, pay: $300,670)
-
How many employees does Timber Pharmaceuticals have?
As Jul 2024, Timber Pharmaceuticals employs 9 workers.
-
When Timber Pharmaceuticals went public?
Timber Pharmaceuticals, Inc. is publicly traded company for more then 11 years since IPO on 8 Sep 2014.
-
What is Timber Pharmaceuticals's official website?
The official website for Timber Pharmaceuticals is timberpharma.com.
-
Where are Timber Pharmaceuticals's headquarters?
Timber Pharmaceuticals is headquartered at 110 Allen Road, Basking Ridge, NJ.
-
How can i contact Timber Pharmaceuticals?
Timber Pharmaceuticals's mailing address is 110 Allen Road, Basking Ridge, NJ and company can be reached via phone at +973 3149577.
Timber Pharmaceuticals company profile:
Timber Pharmaceuticals, Inc.
timberpharma.comAMEX
9
Biotechnology
Healthcare
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. It is also involved in the development of TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. In addition, the company engages in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. It has license agreement with AFT Pharmaceuticals Limited. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.
Basking Ridge, NJ 07920
CIK: 0001504167
ISIN: US8870802084
CUSIP: 887080109
